Sanofi Dengue Vaccine Suffers Mixed Trial Results, But High Unmet Need Could Help It Forward
This article was originally published in The Pink Sheet Daily
The efficacy seen in Sanofi’s Phase IIb dengue vaccine trial was modest. At least one dengue vaccine expert thinks the pharma would stand a better chance if it developed the vaccine as one dose instead of three.
You may also be interested in...
Sanofi plans to build its third manufacturing plant in Vietnam to expand exports into the Association of Southeast Asian Nations trading bloc and meet growing domestic demand. The company’s deep roots in the region via acquisitions give it an edge over other MNCs.
Six-year-old Inviragen may be the biotech of the future.
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.